The Anti-PD-1 MAb Market in the US is expanding as immune checkpoint inhibitors become increasingly important in cancer treatment. Anti-PD-1 monoclonal antibodies (MAbs) work by blocking the programmed cell death protein 1 (PD-1) pathway, helping restore T-cell activity and enhance the immune system’s ability to recognize and attack cancer cells. Market Overview The anti-PD-1 mAb market...